Medical Genetics Unit, Aziende Socio Sanitarie Territoriali (ASST) Santi Paolo e Carlo, Milan, Italy.
Medical Genetics, Department of Health Sciences, Università degli Studi di Milano, Milan, Italy.
Front Endocrinol (Lausanne). 2024 Apr 16;15:1349000. doi: 10.3389/fendo.2024.1349000. eCollection 2024.
Recent advancements in reproductive medicine have guided novel strategies for addressing male infertility, particularly in cases of non-obstructive azoospermia (NOA). Two prominent invasive interventions, namely testicular sperm extraction (TESE) and microdissection TESE (micro-TESE), have emerged as key techniques to retrieve gametes for assisted reproduction technologies (ART). Both heterogeneity and complexity of NOA pose a multifaceted challenge to clinicians, as the invasiveness of these procedures and their unpredictable success underscore the need for more precise guidance. Seminal plasma can be aptly regarded as a liquid biopsy of the male reproductive tract, encompassing secretions from the testes, epididymides, seminal vesicles, bulbourethral glands, and prostate. This fluid harbors a variety of cell-free nucleic acids, microvesicles, proteins, and metabolites intricately linked to gonadal activity. However, despite numerous investigations exploring potential biomarkers from seminal fluid, their widespread inclusion into the clinical practice remains limited. This could be partially due to the complex interplay of diverse clinical and genetic factors inherent to NOA that likely contributes to the absence of definitive biomarkers for residual spermatogenesis. It is conceivable that the integration of clinical data with biomarkers could increase the potential in predicting surgical procedure outcomes and their choice in NOA cases. This comprehensive review addresses the challenge of sperm retrieval in NOA through non-invasive biomarkers. Moreover, we delve into promising perspectives, elucidating innovative approaches grounded in multi-omics methodologies, including genomics, transcriptomics and proteomics. These cutting-edge techniques, combined with the clinical and genetics features of patients, could improve the use of biomarkers in personalized medical approaches, patient counseling, and the decision-making continuum. Finally, Artificial intelligence (AI) holds significant potential in the realm of combining biomarkers and clinical data, also in the context of identifying non-invasive biomarkers for sperm retrieval.
生殖医学的最新进展为解决男性不育症,特别是非梗阻性无精子症(NOA)提供了新的策略。睾丸精子提取(TESE)和显微睾丸精子提取(micro-TESE)这两种主要的侵入性干预措施已经成为辅助生殖技术(ART)获取配子的关键技术。NOA 的异质性和复杂性给临床医生带来了多方面的挑战,因为这些手术的侵入性和不可预测的成功率突显了更精确指导的必要性。精液可以被恰当地视为男性生殖道的液体活检,包含来自睾丸、附睾、精囊、尿道球腺和前列腺的分泌物。这种液体中含有多种游离核酸、微泡、蛋白质和代谢物,与性腺活动密切相关。然而,尽管有许多研究探索了潜在的精液生物标志物,但它们在临床上的广泛应用仍然有限。这可能部分是由于 NOA 固有的多种临床和遗传因素的复杂相互作用,这可能导致没有明确的残余生精功能的生物标志物。可以想象,将临床数据与生物标志物相结合,可以提高预测手术结果及其在 NOA 病例中的选择的潜力。这篇全面的综述通过非侵入性生物标志物来解决 NOA 中的精子提取问题。此外,我们深入探讨了有前途的观点,阐明了基于多组学方法的创新方法,包括基因组学、转录组学和蛋白质组学。这些前沿技术,结合患者的临床和遗传学特征,可以提高生物标志物在个性化医疗方法、患者咨询和决策连续体中的应用。最后,人工智能(AI)在结合生物标志物和临床数据方面具有重要潜力,也可以用于识别精子提取的非侵入性生物标志物。